Sofia Smith

Home

Reels

Eventos

Discover Eventos My Events

Blogs

Mercado

Discover Mercado

Grupos

Discover Grupos My Groups

Páginas

Discover Páginas le gustaba páginas

Más

Popular Posts Discover Posts Financiamiento Ofertas Empleos Courses Foros Películas Juegos

Mercado Blogs Páginas Grupos

Eventos Empleos Ofertas Ver Todo

Upgrade to Pro

Sofia Smith

@smith4u

About

3 Entradas

6 Fotos

0 Videos

seguida por 5 people

Fotos

Sofia Smith agregó una foto Home

2022-12-21 11:18:47 ·

In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.

In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.

Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030

Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031Since John Steele, John Richardson, and Jerzy Olszewski first described PSP in 1964, the neuroscience community has been on the lookout to find a “miracle molecule” or an “elixir” that can cure patients diagnosed with this debilitating disease.With more than 2,000 research studies published...

·3K Views ·0 Vista previa

Please log in to like, share and comment!

Quizás te interese…